The Biopharma Map Is Moving

Good morning, ! This week we’re diving into the FDA expedited IND pilot, GSK’s keeps building its myeloma pipeline, and Asia becoming a biopharma innovation hub. 

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

Join PE150 and Caplink for our AI & Data Insight Breakfast in London. Register here.

— The Healthcare150 Team

MICROSURVEY

HEADLINE OF THE WEEK

FDA Opens a Faster IND Lane: Early Stage Drug Development Could Move Back to the U.S.

The FDA has launched its Expedited IND Pilot, testing a new model designed to shorten the path from preclinical development to first in human trials. Instead of waiting for a complete IND package, the agency can review individual components on a rolling basis, allowing issues across toxicology, clinical design, and CMC to be addressed earlier.

The initial cohort will include just 8 to 10 sponsor and qualified research institution pairs, but the strategic significance is larger than the pilot size. The FDA says the program could eventually inform a broader framework for modernizing early stage development, including closer coordination of IRB review and clinical site activation.

Why it matters: Drug development speed is becoming a competitive variable between markets. If rolling IND review reduces delays without lowering regulatory standards, biotech sponsors could face a materially different calculus on where to run early trials, while CROs, academic medical centers, and clinical infrastructure providers gain a new competitive premium.

Bottom line: The FDA is not accelerating one drug. It is testing whether it can accelerate the system. (More)

PRESENTED BY CAPLINK X PE 150

You’re invited: Where AI Meets Private Equity

Artificial intelligence has moved beyond experimentation. The real question for private equity firms is no longer whether to adopt AI, but how to turn it into measurable value across the investment lifecycle.

On November 18, PE150 and CapLink Group will host the AI / Data & Insight Private Capital Breakfast, an invitation-only gathering at London's May Fair Hotel that will bring together operating partners, deal teams, portfolio executives, and technology leaders to discuss what AI adoption actually looks like inside private equity.

The morning will feature three practitioner-led discussions:

• AI Into Value Creation — How leading firms are transforming AI from dashboards into repeatable value creation playbooks across portfolio companies.

• AI Across the Investment Lifecycle — Practical applications spanning sourcing, due diligence, investment decisions, and portfolio management.

• Building the AI-Enabled Private Equity Firm — The operating models, data strategies, and organizational capabilities required to scale AI successfully.

Interested in attending? Register or request the full agenda here.

Interested in sponsoring? Email [email protected] 

DEAL OF THE WEEK

GSK’s $750M Multiple Myeloma Bet

GSK agreed to acquire global rights to Chimagen Biosciences’ trispecific T-cell engager for up to $750M, adding another next-generation asset to its multiple myeloma pipeline.

The deal extends an existing relationship between the two companies and gives GSK control of a potential best-in-class therapy expected to enter Phase I trials in 2027. The consideration combines upfront and milestone payments, tying much of the economics to future development progress.

For investors, the structure is as relevant as the asset. milestone-based biotech deals allow large pharma companies to access promising science early while limiting capital at risk before clinical validation.

The investor takeaway: Big Pharma is still willing to pay significant headline values for differentiated oncology assets—but increasingly with risk-sharing structures that push consideration behind clinical milestones.

Read more

DEAL TRACKER
Addus HomeCare → AccentCare Personal Care Business | ~$275M
Addus HomeCare (NASDAQ: ADUS) agreed to acquire most of AccentCare’s personal and community care operations for approximately $275M in cash. The acquired business adds roughly $280M in annualized revenue and expands Addus’ multi-state home-care footprint. More

Veracyte → Convergent Genomics | Up to $180M
Veracyte (NASDAQ: VCYT) acquired Convergent Genomics for $150M upfront plus up to $30M in milestones, adding its UroAmp urinary tumor DNA platform to Veracyte’s urology diagnostics portfolio and expanding its bladder cancer monitoring capabilities. More

HCA Healthcare → CHCP | Undisclosed
HCA Healthcare (NYSE: HCA) completed its acquisition of The College of Health Care Professions, bringing a major allied-health education provider in-house as the hospital operator strengthens its clinical workforce pipeline amid persistent healthcare labor constraints. More

Waystar | Potential Sale
Healthcare payments platform Waystar (NASDAQ: WAY) has reportedly hired Evercore and Barclays to explore a potential sale. A transaction would put a scaled public healthcare payments and revenue-cycle platform in play — and could provide a fresh valuation benchmark for HCIT assets. More

REGIONAL FOCUS

Asia’s Biopharma Race Is Becoming a Five-Speed Market

Asia is rapidly strengthening its position as a global biopharma innovation hub—but the region is far from homogeneous.

McKinsey’s assessment of five major Asian markets highlights a widening gap in innovation readiness. China stands out for its combination of strong government support, global regulatory integration, active PE/VC markets, and a scaled entrepreneurial talent pool. South Korea follows with strong public support and talent, although private capital remains comparatively limited.

Elsewhere, the opportunity comes with more visible bottlenecks. India combines a large talent base and highly developed data infrastructure with limited private and public funding, while Japan’s research capabilities are constrained by weaker entrepreneurship and exit options. Singapore offers sophisticated regulatory and R&D infrastructure, but faces limitations in talent depth and capital markets.

The bottom line: “Asia” is becoming too broad a category for biopharma investors. As innovation shifts eastward, the region’s winners may increasingly be determined not just by scientific capabilities, but by the ecosystems that can fund, regulate, scale, and commercialize them.

Read more

INTERESTING ARTICLES